Main Uses of Ovima 28

Ovima 28 is a combined oral contraceptive pill used primarily to prevent pregnancy. It contains two types of female hormones: an estrogen (ethinylestradiol) and a progestogen (levonorgestrel). When taken as intended, these hormones work together to provide effective birth control through several biological mechanisms.

How It Works

The active ingredients in Ovima 28 prevent conception by affecting the reproductive cycle in three main ways:

• Inhibition of Ovulation: The primary action is the suppression of the release of an egg from the ovaries during the monthly cycle.
• Cervical Mucus Alteration: The hormones increase the thickness of the mucus at the neck of the womb (cervix), making it more difficult for sperm to reach an egg.
• Endometrial Changes: The medication alters the lining of the uterus (endometrium), making it less receptive to the implantation of a fertilized egg.

Additional Benefits

Beyond its primary use as a contraceptive, users of combined oral contraceptives like Ovima 28 may experience secondary physiological effects. These can include:

• Menstrual Cycle Regulation: The cycle often becomes more regular and predictable.
• Reduction in Menstrual Symptoms: Periods may become lighter and less painful (reduced dysmenorrhea).
• Management of Iron Deficiency: Because menstrual bleeding is often reduced, there may be a lower risk of developing iron-deficiency anemia.
• Symptom Relief: In some cases, the hormonal stabilization may help alleviate certain symptoms associated with premenstrual syndrome (PMS).

Regulatory References

1. National Institutes of Health (NIH) MedlinePlus overview

Who Can and Cannot Use Ovima 28?

Ovima 28, a combination hormonal contraceptive, is officially indicated for use by females of reproductive potential who have begun their menstrual periods (post-menarche).

However, regulatory authorities strictly define populations who must not use this medication, primarily due to increased risk of serious cardiovascular events or other health complications.

---

Contraindications: Who Must Not Use Ovima 28

Use of Ovima 28 is absolutely prohibited (contraindicated) for individuals with the following official conditions:

• Age and Smoking: Women over 35 years old who smoke.
• Vascular/Thrombotic History: Current or history of deep-vein thrombosis (DVT), pulmonary embolism (PE), stroke, or heart attack.
• Certain Cancers: Known or suspected breast cancer or other estrogen-sensitive malignancies.
• Liver Function: Active liver disease, severe cirrhosis, or liver tumors.
• Hypertension: Uncontrolled high blood pressure (hypertension).

---

Restricted or Conditional Eligibility

Specific timing rules apply to certain populations:

• Postpartum Status: Non-breastfeeding women must wait at least four weeks after delivery before starting Ovima 28.
• Surgery: Use must be stopped at least four weeks before and through two weeks after major surgery or prolonged immobilization.

Use is not indicated before menarche or after menopause, and is not recommended during breastfeeding.

Interactions with other medicines and products

This section summarizes documented interactions strictly based on official regulatory labeling. These interactions primarily involve substances that affect the contraceptive hormones' systemic exposure or those that increase specific risks via additive effects.

---

Documented Interaction Categories

Category	Description and Regulatory Constraint
Hepatitis C Combinations	Co-administration with certain Hepatitis C regimens, such as ombitasvir/paritaprevir/ritonavir (with or without dasabuvir), is contraindicated due to the potential for significant liver enzyme elevations. Regulatory documents require discontinuation of hormonal contraceptives before starting these regimens.
Enzyme Inducers	Medicines that are strong inducers of hepatic enzymes, particularly CYP3A4, may significantly decrease the effectiveness of Ovima 28. Use with these substances (e.g., specific anticonvulsants or antituberculosis drugs) requires patients to use a nonhormonal back-up method during and for a specified time after discontinuation of the inducer.
Pharmacodynamic Agents	Concomitant use with specific medicines, such as oral tranexamic acid or fezolinetaht, is contraindicated due to the potential for severe additive effects, such as an increased risk of thrombotic events or elevated liver enzymes.

---

Administration Requirements

Specific administration rules apply to ensure efficacy. If vomiting or severe diarrhea occurs within 3 to 4 hours after taking a tablet, the regulatory procedure for a missed tablet must be followed due to potential incomplete absorption. Co-administration of other drugs whose levels are sensitive to CYP enzyme inhibition may result in increased exposure to those drugs.

Ovima 28 contains the progestin levonorgestrel and the estrogen ethinyl estradiol. The pharmacodynamic mechanism involves suppression of gonadotropins, primarily achieved by a negative feedback loop at the level of the hypothalamus and pituitary gland.

Levonorgestrel acts as an agonist at the progesterone receptor, while ethinyl estradiol is an agonist at the estrogen receptor. The combined action decreases the secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus, subsequently reducing the pituitary release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This suppression prevents the LH surge, which is the requisite intracellular signal cascade for follicular rupture and subsequent oocyte release. Inhibition of ovulation is the primary system-level physiological consequence.

Secondary actions modulate the reproductive tract environment: the progestin component induces a reduction in cervical mucus hydration, leading to a state of increased viscosity that mechanically impedes sperm migration into the upper reproductive tract. Concurrently, the endometrial lining undergoes structural and morphological changes, reducing its receptivity to blastocyst adherence.

Ovima 28 is administered orally as a tablet, consistent with its classification as an oral contraceptive. The usage is structured around a 28-day continuous cycle, a standard protocol for combination oral contraceptives. The regimen requires taking one tablet once daily, establishing a consistent systemic concentration of Ethinyl Estradiol and Levonorgestrel.

Official instructions mandate the dose be consumed at approximately the same time each day, and the tablets may be swallowed whole with or without food. The treatment requires strict procedural adherence to the sequence indicated on the package; the active and inactive tablets must be taken in the precise order specified for the 28-day period. Additionally, the prescribing information details specific protocols for handling a missed dose, depending on the timing and the tablet type missed.

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral
Dosing Schedule	One tablet daily, following a 28-day cycle of 21 active and 7 inactive tablets.
Timing	Must be taken at the same time each day; can be taken with or without food.
Procedural Condition	Tablets must be consumed in the exact sequential order shown on the package.
Population	Intended for use in women of reproductive age

The official instructions establish a continuous, cyclic administration pattern using the oral route to ensure systemic exposure. This protocol dictates the once-daily frequency, mandates the use of both the active and inactive tablets over repeating 28-day periods, and emphasizes procedural adherence to the specific tablet sequence and timing to maintain the integrity of the usage schedule.

Ovima 28 is a combination hormonal contraceptive containing ethinyl estradiol (EE) and levonorgestrel (LNG), with a dosing schedule of 21 active pills and 7 inactive (reminder) pills. The clinical evidence for this combination primarily focuses on its established effectiveness for the prevention of pregnancy.

Efficacy and Contraceptive Reliability

Studies involving combination oral contraceptives (COCs) containing 30 µg EE and 150 µg LNG have consistently evaluated contraceptive reliability, typically measured using the Pearl Index (PI), which calculates the number of pregnancies per 100 woman-years of use. Clinical trials generally report low rates of pregnancy when the medication is used correctly.

• Typical Use: The PI for typical use (which includes missed or delayed pills) tends to be higher than the PI for perfect use, reflecting real-world conditions.
• Mechanism of Action: The combination of hormones works primarily by suppressing the release of eggs from the ovary (ovulation), and by causing changes to the cervical mucus and the lining of the uterus.

Safety Profile and Risk Monitoring

Research emphasizes the importance of understanding the safety profile, which is comparable to other low-dose COCs. The use of any COC is associated with increased, though still small, risks of serious conditions, including venous thromboembolism (VTE), stroke, and myocardial infarction, particularly in women with underlying risk factors such as smoking or age over 35.

• Adverse Events (AEs): Common AEs observed in clinical trials and meta-analyses generally involve hormone-related effects such as nausea, headache, and changes in bleeding patterns (spotting or breakthrough bleeding).
• Special Populations: Clinical monitoring and specific studies are particularly relevant for individuals with certain pre-existing conditions, such as liver disease or a history of migraine with aura, as these may increase contraindications or require careful risk assessment before initiation.

Key Studies & References

1. Combined hormonal contraception and the risk of venous thromboembolism: a guideline (2016) | American Society for Reproductive Medicine
2. Ovima Factsheet, Uses & Common Side Effects - Rexall (Product Monograph/Information Summary)
3. An Overview of Current Contraceptive Modalities and Historical Perspectives: A Review (Includes Pearl Index Methodology)

Common questions about Ovima 28 (FAQ)

---

Q: How quickly does Ovima 28 start to show its effects?

Official product information describes that contraceptive protection begins immediately if the medication is started on the first day of the menstrual cycle. If the product is started at any other time, regulatory documents state that a non-hormonal back-up method is required for the first 7 days, as described in the official instructions.

Q: Is Ovima 28 meant for long-term use?

Ovima 28 is administered in continuous, repeating 28-day cycles for conception control. According to official documents, it is intended for use by women of reproductive potential, and use is not recommended after menopause, according to official documents.

Q: Can Ovima 28 affect my ability to drive or operate machinery?

The official safety profile reports common adverse reactions such as headache and dizziness. While the label does not provide a direct warning about driving, such effects may be experienced, which could impact concentration.

Q: Is it common to feel certain side effects when starting Ovima 28?

Yes, common side effects such as nausea, headache, and irregular uterine bleeding (spotting) are reported to be most frequent during the initial three months of starting the treatment. The frequency of these effects often diminishes after the initial months of use.

Q: Why is Ovima 28 often prescribed as a 28-day regimen?

The administration involves a continuous, cyclic schedule of 21 active (hormone-containing) tablets followed by 7 inactive (reminder) tablets. This 28-day protocol is a standard approach for combined oral contraceptives, used to maintain a consistent menstrual cycle rhythm.

Q: What is the significance of the tablet colors or markings on Ovima 28?

The tablets in the 28-day pack are differentiated by color or markings to help the patient distinguish between the active tablets, which contain the hormones, and the inactive or inert tablets. It is required that the tablets are taken in the specific sequence indicated on the packaging.

Q: Is it normal for Ovima 28 to affect mood or sleep?

Adverse event data documented for this medication includes reports of mood changes and depression. These effects are related to the Central Nervous System. However, changes to sleep patterns are not generally listed in the regulatory documents.

Q: Are there any long-term health concerns associated with Ovima 28 use?

Official labeling notes that use is associated with an increased, though small, risk of serious cardiovascular events, including venous thromboembolism (VTE), stroke, and heart attack. The risk of VTE is documented as highest during the first year of treatment.

Q: What is the difference between Ovima 28 and other similar-sounding treatments?

Ovima 28 is defined by its specific active ingredients: the progestin levonorgestrel and the estrogen ethinyl estradiol. Official product descriptions indicate that this factual composition information can be referenced when comparing against other products.

Q: Are there any specific vitamins or supplements that interact with Ovima 28?

Regulatory information advises caution regarding certain supplements, specifically warning that herbal products that induce liver enzymes (such as St. John’s Wort) may decrease the effectiveness of the drug. Some official documents also address the potential impact on the body’s levels of vitamins, such as folic acid.

Q: Can men use Ovima 28 for any condition?

Official indications state the drug is for the prevention of pregnancy in females of reproductive potential. The regulatory documents do not state any indication for use in men.

Q: What happens if I accidentally miss a dose of Ovima 28?

Official labeling provides specific and detailed instructions for handling a missed dose. These protocols vary depending on which week of the 28-day cycle the tablet was missed and how many tablets were missed. The procedure outlined in the official prescribing information should be followed.

Q: Does taking Ovima 28 affect the results of common lab tests?

Yes, official documentation indicates that Ovima 28 may affect the results of certain laboratory tests, including those that measure blood clotting factors, thyroid function, and cholesterol levels. Official labeling states that healthcare providers should be informed of use prior to testing.

Q: Is it possible to be allergic to an ingredient in Ovima 28?

The product is officially contraindicated (prohibited) for individuals who are known to be hypersensitive (allergic) to any of the active or inactive components of the tablet. The contraindications section addresses hypersensitivity to any of the tablet's components.

Q: Are there known interactions between Ovima 28 and herbal products?

Yes, the product labeling includes a specific warning about herbal products, particularly those that are known to induce certain liver enzymes. Use of these products (like St. John’s Wort) may decrease the effectiveness of the contraceptive and may require the use of a non-hormonal back-up method.

Q: How long does Ovima 28 stay in the system after stopping treatment?

Regulatory data on the drug’s pharmacokinetics indicates that the hormones are usually cleared from the system within 3 to 7 days after the last active tablet is taken. The time it takes for the hormones to be processed by the body is usually measured in hours.

Q: Does Ovima 28 have a Boxed Warning listed by the FDA?

Yes, the official FDA labeling includes a Boxed Warning, which is the strongest type of warning the agency requires. This warning pertains to the risk of Cigarette Smoking and Serious Cardiovascular Events, stating that the risk increases with age, especially in women over 35 who smoke.

Q: What kind of safety monitoring is usually recommended while on Ovima 28?

Official warnings and precautions sections describe the need for monitoring blood pressure while taking this medication. Monitoring of blood pressure is required, and special caution is applied to those with pre-existing conditions.

Q: Is there a generic version of Ovima 28 available?

The specific combination of the two active ingredients, levonorgestrel and ethinyl estradiol, is widely available as a generic medication and under many different brand names, as described in public drug listings from authoritative sources like the NIH.

How to Store and Dispose of Ovima 28: Official Regulatory Information

This section outlines the mandatory storage, stability, and disposal requirements as stated in official regulatory documentation.

Requirement	Details
Storage Temperature	Store below 25^circmathrmC and maintain between 15^circmathrmC - 25^circmathrmC. Do not freeze or refrigerate.
Protection	Protect from light and moisture. Keep the medicine in its original container.
Stability	The unopened shelf-life is 36 months. After the container is first opened, the medicine must be used within 6 months.
Child Safety	Keep Ovima 28 out of the sight and reach of children.
Disposal	Do not dispose of this medicine in household waste or via wastewater. Return any unused or expired product to a pharmacist or authorized disposal collector for proper pharmaceutical waste management.